安杰思收盘上涨1.78%，滚动市盈率16.24倍，总市值48.22亿元

Core Viewpoint - Anjias Medical Technology Co., Ltd. has shown a stable performance in the medical device industry, with a current PE ratio of 16.24, significantly lower than the industry average of 48.90, indicating potential undervaluation in comparison to peers [1][2]. Company Overview - Anjias specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, primarily focusing on GI, EMR/ESD, and ERCP diagnostic series [1]. - The company has received seven significant government honors, including recognition as a "Zhejiang Provincial Enterprise Technology Center" and "Zhejiang Provincial High-Growth Biopharmaceutical Enterprise" [1]. Financial Performance - For Q1 2025, Anjias reported a revenue of 129 million yuan, representing a year-on-year increase of 15.27% [1]. - The net profit for the same period was approximately 56.25 million yuan, reflecting a year-on-year growth of 6.57% [1]. - The gross profit margin stood at 70.68%, indicating strong profitability [1]. Shareholder Information - As of April 18, 2025, Anjias had 5,174 shareholders, a decrease of 87 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Industry Comparison - Anjias ranks 40th in terms of PE ratio within the medical device industry, which has an average PE of 48.90 and a median of 36.41 [1][2].